1167 Jacobio Pharmaceuticals Group Co., Ltd. HKEX · China

Jacobio Pharmaceuticals Group Co. (1167) news

Jacobio Pharmaceuticals Group Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1167, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Jacobio Pharmaceuticals Group Co. news

We have not published a story on Jacobio Pharmaceuticals Group Co. yet. When there is news, it will appear here.

Questions about Jacobio Pharmaceuticals Group Co.

What is the ticker symbol of Jacobio Pharmaceuticals Group Co.?

Jacobio Pharmaceuticals Group Co., Ltd. trades under the ticker 1167 on HKEX.

Where is Jacobio Pharmaceuticals Group Co. listed?

Jacobio Pharmaceuticals Group Co., Ltd. is listed on HKEX. Our directory also records these other listings: LS:A2QK1R.

Which country or territory is Jacobio Pharmaceuticals Group Co. listed under?

Our directory records Jacobio Pharmaceuticals Group Co., Ltd. under China.

What does Jacobio Pharmaceuticals Group Co. do?

Our directory classifies Jacobio Pharmaceuticals Group Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Jacobio Pharmaceuticals Group Co.?

The ISIN recorded for Jacobio Pharmaceuticals Group Co., Ltd. is KYG4987A1094.

Does aibio.space cover Jacobio Pharmaceuticals Group Co.?

aibio.space lists Jacobio Pharmaceuticals Group Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Jacobio Pharmaceuticals Group Co.?

Companies in our directory listed in the same country and business area as Jacobio Pharmaceuticals Group Co.: Shanghai Serum Bio-Technology Co., HJ Science Co., Edding Genor Group Holdings, Shanghai Shen Lian Biomedical, Alphamab Oncology, Shanghai ZJ Bio-Tech Co..

Investor discussion: Jacobio Pharmaceuticals Group Co.

Members talk about Jacobio Pharmaceuticals Group Co. (1167). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Jacobio Pharmaceuticals Group Co., newest first. Each line links the filing it comes from.

Apr 24, 2026Financings
Share or debt issue: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING. Source
May 14, 2025Financings
Share or debt issue: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Jacobio Pharmaceuticals Group Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Aug 24, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND APPOINTMENT OF VICE CHAIRPERSON OF THE BOARD AND CHANGES IN SENIOR MANAGEMENT
Aug 10, 2026HKEXnews
POSITIVE PROFIT ALERT
Jul 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE IIA CLINICAL TRIAL OF BET INHIBITOR JAB-8263 IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHINA
Jul 19, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO ANNOUNCES FIRST PATIENT DOSED IN CHINA FOR PHASE IB/III CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE THERAPY FOR KRAS-MUTANT PANCREATIC CANCER
Jun 7, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
Jun 5, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 5, 2026
May 18, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE AND CASH RESERVE UPDATE
Apr 24, 2026HKEXnews
NOTICE OF 2026 ANNUAL GENERAL MEETING
Apr 24, 2026HKEXnews
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
Mar 30, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED $100 MILLION UPFRONT PAYMENT FROM ASTRAZENECA UNDER THE LICENSE AND COOPERATION AGREEMENT FOR THE PAN-KRAS INHIBITOR JAB-23E73
Mar 10, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Dec 21, 2025HKEXnews
INSIDE INFORMATION LICENCE AND COLLABORATION AGREEMENT WITH ASTRAZENECA FOR PAN-KRAS INHIBITOR JAB-23E73
Dec 2, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED UPFRONT PAYMENT UPON THE CAPITAL INCREASE AGREEMENT AND EQUITY TRANSFER AGREEMENT
Nov 30, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO'S KRAS G12C AND SHP2 COMBINATION THERAPY PUBLISHED IN THE LANCET RESPIRATORY MEDICINE
Nov 12, 2025HKEXnews
APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER
Oct 23, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED PRECLINICAL DATA OF PAN-KRAS INHIBITOR JAB-23E73 AT THE AACR-NCI-EORTC 2025 INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
Oct 15, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT ENTERING INTO THE CAPITAL INCREASE AGREEMENT AND EQUITY TRANSFER AGREEMENT
Sep 25, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT CHANGE IN SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT AND UPDATES ON ON-MARKET SHARE REPURCHASE BY THE COMPANY
Sep 3, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT FURTHER INCREASE SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT
Aug 29, 2025HKEXnews
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1167 on TradingView.

Listing details

Company: Jacobio Pharmaceuticals Group Co., Ltd.
Ticker: 1167
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: KYG4987A1094
Other listed symbols: LS:A2QK1R
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction